Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tildrakizumab in Active Psoriatic Arthritis
NCT02980692Phase 2Completed
- Sponsor
- Sun Pharma
- Start
- Apr 2017
- Primary completion
- Mar 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tildrakizumab in psoriatic arthritis (PsA) (5 arms), sponsored by Sun Pharma. Primary endpoint: American College of Rheumatology 20 Response Rate at 24 weeks. Started Apr 2017; status: completed.
02
Drugs
tildrakizumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT02980692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02980692.